Skip to main content
Equibles

ORBIMED ADVISORS LLC

Position in CGON — CG Oncology, Inc.

CIK 1055951 New York, NY
Back to CGON Full portfolio

Position in CGON

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$69,117,440
+$4,938,730 QoQ
Shares Held
972,800
+2.6% QoQ
Ownership
1.10%
of shares outstanding
% of Portfolio
1.37%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
8 quarters on record
Voting authority Sole 21% Shared 0% None 79%

Common Shares in CGON Over Time

Shares Held

Position Value (USD)

Derivatives in CGON

reported options exposure · as of Jun 30, 2025
CallValue
$3,900,000
CallShares
150,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ORBIMED ADVISORS LLC holds $3,639,640,835 across 90 Biotechnology names. CGON ranks #14 (1.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 EWTX
Edgewise Therapeutics, Inc.
 15,518,492 $630,516,329
2 ELVN
Enliven Therapeutics, Inc.
 6,776,632 $343,914,074
3 MBX
MBX Biosciences, Inc.
 3,428,736 $189,266,227
4 GPCR
Structure Therapeutics Inc.
 2,209,400 $118,578,498
5 SION
Sionna Therapeutics, Inc.
 2,555,877 $112,433,029
6 CRVS
Corvus Pharmaceuticals, Inc.
 7,165,006 $107,045,189
7 AVBP
ArriVent BioPharma, Inc.
 3,027,328 $105,169,374
8 ARGX
Argenx SE
 92,880 $86,171,277

All Filings in CGON

Export CSV
9 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $69,117,440 972,800
2026-03-31 $64,178,710 948,267
2025-12-31 $62,967,156 1,516,550
2025-09-30 $69,557,518 1,726,850
2025-06-30 $48,824,100 1,877,850
2025-06-30 $3,900,000 150,000
2025-03-31 $60,539,133 2,471,994
2024-12-31 $41,044,349 1,431,114
2024-09-30 $26,075,731 691,114